Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Association Between Disease-Modifying Therapies Prescribed to Persons with Multiple Sclerosis and Cancer: a WHO Pharmacovigilance Database Analysis
Charles Dolladille, Basile Chrétien, Laure Peyro‐Saint‐Paul, et al.
Neurotherapeutics (2021) Vol. 18, Iss. 3, pp. 1657-1664
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

Novel potential pharmacological applications of dimethyl fumarate—an overview and update
Giorgia Bresciani, Federico Manai, Sergio Davinelli, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 27
Multiple sclerosis: time for early treatment with high-efficacy drugs
Krzysztof Selmaj, Bruce Cree, Michael Barnett, et al.
Journal of Neurology (2023) Vol. 271, Iss. 1, pp. 105-115
Open Access | Times Cited: 27
Cancer and multiple sclerosis: 2023 recommendations from the French Multiple Sclerosis Society
Nicolas Collongues, Françoise Durand‐Dubief, Christine Lebrun‐Frénay, et al.
Multiple Sclerosis Journal (2024) Vol. 30, Iss. 7, pp. 899-924
Closed Access | Times Cited: 6
Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: Methotrexate, alkylating agents, biologics, and small molecule inhibitors
Margaret Ann Kreher, Sailesh Konda, Mary Margaret B. Noland, et al.
Journal of the American Academy of Dermatology (2022) Vol. 88, Iss. 3, pp. 534-542
Closed Access | Times Cited: 28
Cancer in multiple sclerosis patients following prolonged exposure to disease-modifying therapies (DMTs): a systematic review and meta-analysis
Vasileios Giannopapas, Vassiliki Smyrni, Dimitrios K. Kitsos, et al.
Journal of Neurology (2025) Vol. 272, Iss. 2
Open Access
Association between antidepressant drugs and falls in older adults: a mediation analysis in the World Health Organization’s pharmacovigilance database
Elise-Marie Minoc, Cédric Villain, Basile Chrétien, et al.
Therapies (2025)
Open Access
Current and Emerging Treatment Options in Pediatric Onset Multiple Sclerosis
Artemis Mavridi, Maria Eleni Bompou, Aine Redmond, et al.
Sclerosis (2024) Vol. 2, Iss. 2, pp. 88-107
Open Access | Times Cited: 3
Flow cytometry identifies changes in peripheral and intrathecal lymphocyte patterns in CNS autoimmune disorders and primary CNS malignancies
Saskia Räuber, Andreas Schulte‐Mecklenbeck, Alice Willison, et al.
Journal of Neuroinflammation (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 3
Adverse Drug Reactions with Drugs Used in Multiple Sclerosis: An Analysis from the Italian Pharmacovigilance Database
María Antonietta Barbieri, Emanuela Elisa Sorbara, Alessandro Battaglia, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 15
Multiple sclerosis and breast cancer risk: a meta-analysis of observational and Mendelian randomization studies
Tian Fang, Zhihao Zhang, Huijie Zhou, et al.
Frontiers in Neuroinformatics (2023) Vol. 17
Open Access | Times Cited: 6
The safety and efficacy of fingolimod: Real-world data from a long-term, non-interventional study on the treatment of RRMS patients spanning up to 5 years from Hungary
Tamás Biernacki, Dániel Sandi, Judit Füvesi, et al.
PLoS ONE (2022) Vol. 17, Iss. 4, pp. e0267346-e0267346
Open Access | Times Cited: 8
Risk of cervical pre-cancer and cancer in women with multiple sclerosis exposed to high efficacy disease modifying therapies
Francesca Bridge, Julia Brotherton, Yi Chao Foong, et al.
Frontiers in Neurology (2023) Vol. 14
Open Access | Times Cited: 4
Clinical use of dimethyl fumarate in multiple sclerosis treatment: an update to include China, using a modified Delphi method
Ralf Gold, Michael Barnett, Andrew Chan, et al.
Therapeutic Advances in Neurological Disorders (2023) Vol. 16
Open Access | Times Cited: 4
Highly Active Relapsing-Remitting Multiple Sclerosis with Neurofibromatosis Type 1: Radiological Aspects and Therapeutic Challenges – Case Report
Marios Lemonaris, Kleopas A. Kleopa
Case Reports in Neurology (2024) Vol. 16, Iss. 1, pp. 48-54
Open Access | Times Cited: 1
[Translated article] Risk of Skin Cancer Associated with Disease-Modifying Therapies in Multiple Sclerosis: A Comprehensive Evidence Review
Magí Brufau‐Cochs, Miguel Mansilla‐Polo, D. Morgado‐Carrasco
Actas Dermo-Sifiliográficas (2024) Vol. 115, Iss. 8, pp. T781-T790
Open Access | Times Cited: 1
Dermatological Neoplastic Diseases Complicating Treatment with Monoclonal Antibody for Multiple Sclerosis
Floriana Bile, Maddalena Sparaco, Eleonora Ruocco, et al.
(2024)
Open Access | Times Cited: 1
Exploring the role of sex hormones and gender diversity in multiple sclerosis
Cassie Nesbitt, Anneke van der Walt, Helmut Butzkueven, et al.
Nature Reviews Neurology (2024)
Closed Access | Times Cited: 1
Incidence of cancer in patients with multiple sclerosis (MS) who were treated with fingolimod: A systematic review and meta-analysis
Mozhde Askari, Omid Mirmosayyeb, Elham Moases Ghaffary, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 59, pp. 103680-103680
Open Access | Times Cited: 6
Cancer risk, disease-modifying therapy, and age in multiple sclerosis: A retrospective population-based cohort study
Jamie Greenfield, Luanne M. Metz, Amir Khakban, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 80, pp. 105091-105091
Closed Access | Times Cited: 3
Medications for Multiple Sclerosis and Risk of Malignancy: What Next?
Daniel B. Horton, Anthony T. Reder
Neurotherapeutics (2021) Vol. 18, Iss. 3, pp. 1650-1653
Open Access | Times Cited: 6
Co-occurrence of glioma and multiple sclerosis: Prevailing theories and emerging therapies
Enoch Kim, Marla C. Fortoul, Derek Weimer, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 79, pp. 105027-105027
Closed Access | Times Cited: 2
Association between antidepressant use and delirium in older adults: an analysis of the World Health Organization’s global pharmacovigilance database
Elise-Marie Minoc, Cédric Villain, Soumia Benbrika, et al.
Research Square (Research Square) (2024)
Open Access
Riesgo de cáncer cutáneo asociado a terapias modificadoras de la enfermedad en la esclerosis múltiple: revisión narrativa de la evidencia actual
Magí Brufau‐Cochs, Miguel Mansilla‐Polo, D. Morgado‐Carrasco
Actas Dermo-Sifiliográficas (2024) Vol. 115, Iss. 8, pp. 781-790
Open Access
Association between antidepressant use and delirium in older adults: an analysis of the World Health Organization’s global pharmacovigilance database
Elise-Marie Minoc, Cédric Villain, Soumia Benbrika, et al.
BMC Geriatrics (2024) Vol. 24, Iss. 1
Open Access
Data-driven risk/benefit estimator for multiple sclerosis therapies
Bibiana Bielekova, Tianxia Wu, Péter Kósa, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Page 1 - Next Page

Scroll to top